Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: Results from the ESCALATOR study

Ali Taher*, Mohsen S. Elalfy, Kusai Al Zir, Shahina Daar, Abdullah Al Jefri, Dany Habr, Ulrike Kriemler-Krahn, Bernard Roubert, Amal El-Beshlawy

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

This analysis evaluated the effects of deferasirox on liver iron concentration in moderate and heavily iron-overloaded patients with β-thalassaemia from the ESCALATOR trial (n=231). Mean liver iron concentrations (LIC) decreased significantly from 21.1±8.2 to 14.2±12.1mg Fe/g dry weight (dw) at 2yr (P<0.001) in patients with LIC ≥7mg Fe/g dw at baseline; patients with LIC <7mg Fe/g dw maintained these levels over the treatment period. The proportion of patients with LIC <7mg Fe/g dw increased from 9.4% at core baseline to 39.3% by the end of year 2. The results showed that deferasirox enabled therapeutic goals to be achieved, by maintaining LIC in patients with LIC <7mg Fe/g dw at a mean dose of 22.4±5.2mg/kg/d and significantly reducing LIC in patients with LIC ≥7mg Fe/g dw at a mean dose of 25.7±4.2mg/kg/d, along with a manageable safety profile.

Original languageEnglish
Pages (from-to)349-354
Number of pages6
JournalEuropean Journal of Haematology
Volume87
Issue number4
DOIs
Publication statusPublished - Oct 2011
Externally publishedYes

Keywords

  • Deferasirox
  • Efficacy
  • Iron chelation therapy
  • Iron overload
  • β-thalassaemia

ASJC Scopus subject areas

  • Hematology

Fingerprint

Dive into the research topics of 'Achieving treatment goals of reducing or maintaining body iron burden with deferasirox in patients with β-thalassaemia: Results from the ESCALATOR study'. Together they form a unique fingerprint.

Cite this